A placebo-controlled study of pyritinol ('Encephabol') in dementia.

Abstract	A double-blind, placebo-controlled trial was carried out on 40 patients suffering from moderately advanced dementia. The patients were allocated randomly either pyritinol (800 mg daily) or identical placebo for 3 months. Assessments using a modified Crichton Geriatric Behavioural Rating Scale were made pre-treatment and monthly up to 3 months, and then at follow-up at 6 months. Patients on pyritinol showed significantly higher levels of improvement than did those on placebo. Laboratory tests conducted throughout remained within normal limits for both groups.
Authors	A J Cooper, R V Magnus
Journal	Pharmatherapeutica (Pharmatherapeutica) Vol. 2 Issue 5 Pg. 317-22 ( 1980) ISSN: 0308-051X [Print] England
PMID	7001490 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Pyridines Pyrithioxin Glucose
Topics	Aged Analysis of Variance Brain (metabolism) Clinical Trials as Topic Dementia (drug therapy) Double-Blind Method Female Glucose (metabolism) Humans Male Middle Aged Pyridines (therapeutic use) Pyrithioxin (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!